This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Other Congenital Malformations of Aortic and Mitral Valves대동맥판 및 승모판의 기타 선천기형

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: Q23.8 | Special Copayment Reduction: V147 (rare disease)
B. SynonymsOther congenital malformations of aortic and mitral valves
C. Adult onsetLikelihood of first onset in adulthood low~moderate — Q23.8 is a code covering other congenital aortic and mitral valve malformations not falling under Q23.0~Q23.4; depending on the degree of dysplasia and the condition, they may be found in childhood or, if mild, first diagnosed in adulthood.
1. HistoryQ23.8 is an 'other' category that includes various rare malformations of the aortic and mitral valves (quadricuspid valve, cusp defect, etc.).
2. CausesVarious abnormalities in aortic and mitral valve development; quadricuspid valve, cusp defect, valve perforation, excess tissue, etc.
3. GeneticsMostly sporadic; NOTCH1 and NKX2.5 variants associated with some malformations; need to check for associated syndromes.
4. General epidemiologyA collection of rare or very rare malformations; quadricuspid aortic valve is ultra-rare at about 0.008%.
5. PathophysiologyDepending on the dysplastic valve structure, regurgitation (incomplete closure) or stenosis (reduced orifice) → left ventricular load.
6. SymptomsDepending on the degree of dysplasia, from asymptomatic to symptoms of regurgitation or stenosis; detection of a heart murmur is a common first clue.
7. SignsSystolic/diastolic murmurs depending on the type of valve dysplasia; outflow tract murmur in LVOTO; thrill may be palpable.
8. ScreeningAuscultation screening of newborns and children; frequent incidental detection in adulthood; echocardiographic screening with familial clustering.
9. DiagnosisEchocardiography is the standard; cardiac MRI for detailed anatomical evaluation; exercise stress testing as a complement in LVOTO.
10. TreatmentIndividualized treatment according to the severity of regurgitation or stenosis; valve repair or replacement; surgical resection for LVOTO.
11. PrognosisVaries by type and severity of dysplasia; good prognosis with early diagnosis and timely surgery.
12. PreventionPrevention of infective endocarditis; regular echocardiographic follow-up; exercise restriction (in LVOTO); echocardiographic screening of family members.
13. References10 major clinical guidelines and original papers

1. History

In ICD-10, code Q23.8 is a residual code covering all other congenital malformations of the aortic and mitral valves not falling under Q23.0 (congenital aortic valve stenosis), Q23.1 (bicuspid aortic valve), Q23.2 (congenital mitral stenosis), Q23.3 (congenital mitral insufficiency) or Q23.4 (HLHS). It is therefore not a single clinical entity but a collection of various rare dysplasias.

Historically, the malformations that can be included in this code have long been described individually. Quadricuspid aortic valve was first reported by Balington in 1862, and since then only a few hundred cases have been reported as an extremely rare malformation. Rare malformations such as isolated cusp defect of the aortic valve, valve perforation and ectopic valvar tissue are also included in this code. Among the various forms of mitral valve dysplasia, those not falling under Q23.2~Q23.3, for example congenital calcification of the valve annulus, accessory mitral valve tissue and abnormalities of connecting fibrous tissue, are also classified as Q23.8.

With advances in modern echocardiography and cardiac MRI, various valve dysplasias that were previously undetected are being diagnosed clinically, and use of code Q23.8 is increasing. The clinical significance of rare valve malformations is determined by whether regurgitation or stenosis develops and by the risk of infective endocarditis.


2. Causes

The causes of the other congenital malformations included in Q23.8 vary according to the anatomical characteristics of each dysplasia.

Quadricuspid Aortic Valve (QAV): An extremely rare malformation in which the aortic valve consists of four cusps. Incomplete closure due to unequal cusp sizes causes regurgitation. It is explained by a mechanism in which additional division occurs during embryonic valve cusp formation.

Congenital aortic regurgitation (in a simple dysplastic valve): Regurgitation due to dysplasia of the valve itself in the absence of cusp size mismatch, cusp prolapse or annular dilation.

Accessory Mitral Valve Tissue: A rare malformation in which accessory mitral valve tissue protrudes into the left ventricular outflow tract, causing outflow tract obstruction (LVOTO). It also includes cases in which an anomalous chord crosses the outflow tract.

Congenital abnormalities of the valve annulus: Congenital abnormal structures of the aortic or mitral annulus (annular dilation, fibrous tissue defects, etc.) cause valve insufficiency.

Embryologically, abnormal migration and differentiation of cardiac neural crest cells, abnormal endothelial-to-mesenchymal transition (EndoMT) and errors in the valve remodeling stage have been proposed as mechanisms, and genetic causes are mostly sporadic.


3. Genetics

The genetic basis of the other congenital aortic and mitral valve malformations included in Q23.8 is diverse, and most occur sporadically.

For quadricuspid aortic valve (QAV), reported associations with specific gene variants are rare, and most cases occur sporadically. The genetic cause of malformations such as accessory mitral valve tissue is also often unclear.

NOTCH1 (9q34.3) and NKX2.5 (5q35.1) variants have been reported in some malformations, but these are not limited to specific Q23.8 malformations and are broadly associated with various valve malformations. When malformations associated with connective tissue disorders (Marfan syndrome, Ehlers-Danlos syndrome) are classified as Q23.8, variants in genes such as FBN1 and COL5A1 are checked.

When multiple malformations are present or a specific syndrome is suspected, chromosomal microarray or whole exome sequencing is performed. When Q23.8 is diagnosed, it is recommended to always evaluate for associated cardiac malformations and to review the possibility of a syndromic cause.


4. General epidemiology

Because Q23.8 is not a single malformation but an 'other' residual code, its collective prevalence is difficult to estimate. The individual malformations included are mostly very rare.

Quadricuspid aortic valve (QAV): An ultra-rare malformation with only about 200~300 cumulative cases reported in the literature worldwide. Its prevalence is estimated at about 0.003~0.008%. It is slightly more common in males and is mostly found incidentally on echocardiography in adulthood.

Accessory mitral valve tissue: A rare malformation accounting for about 0.5% or less of all left ventricular outflow tract obstruction. It is found in childhood with symptoms of outflow tract obstruction or incidentally on echocardiography.

Independent statistics on the number of patients classified as Q23.8 in Korea are scarce, and they are managed within the Special Copayment Reduction (V147) registration system. With the spread of echocardiography, the frequency of diagnosis of these rare malformations is increasing compared with the past.


5. Pathophysiology

The pathophysiology of the malformations included in Q23.8 takes two main directions depending on the type of anatomical dysplasia.

Regurgitation-predominant type: In quadricuspid aortic valve, the four cusps are unequal in size, so systolic ejection is possible to some extent, but complete diastolic closure is impossible and regurgitation occurs. As the regurgitant volume increases, the course follows left ventricular volume overload → eccentric hypertrophy → diastolic dysfunction → decline in systolic function.

Outflow tract obstruction type: When accessory mitral valve tissue or an anomalous chord occupies the left ventricular outflow tract (LVOTO), the velocity of blood flow through it increases and left ventricular pressure overload develops. The Venturi effect may pull the anterior mitral leaflet toward the outflow tract (SAM, systolic anterior motion), causing secondary regurgitation.

Risk of infective endocarditis: Dysplastic valves have valve surface irregularities and turbulence that make them susceptible to bacterial adhesion, so the risk of infective endocarditis increases.


6. Symptoms

Symptoms of the malformations included in Q23.8 range from asymptomatic to severe heart failure depending on the type and severity of dysplasia.

Quadricuspid aortic valve: With mild regurgitation, patients remain asymptomatic for decades, and incidental detection by heart murmur is common. As regurgitation progresses, exercise intolerance and dyspnea develop, and with severe regurgitation, angina and symptoms of heart failure appear.

LVOTO due to accessory mitral valve tissue: Exertional dyspnea, chest pain and syncope may occur. When severe, the symptom pattern resembles hypertrophic cardiomyopathy (HOCM).

Mild dysplasia: Most patients remain asymptomatic, and it is found incidentally on routine checkup echocardiography or echocardiography performed for other purposes.

When complicated by infective endocarditis: Fever, chills, a new heart murmur and embolic symptoms (stroke, pulmonary embolism) appear.


7. Signs

Physical findings of Q23.8 malformations vary by anatomical type.

Quadricuspid aortic valve regurgitation: A diastolic regurgitant murmur is heard at the 3rd~4th intercostal spaces along the left sternal border. With moderate or greater regurgitation, widened pulse pressure, a rapid and forceful pulse (Corrigan pulse) and a hyperdynamic apical impulse appear.

LVOTO (accessory mitral valve tissue): A systolic ejection murmur is heard at the lower sternal border or left sternal border, characteristically increasing with the Valsalva maneuver (similar to hypertrophic cardiomyopathy). A thrill may be palpable.

Electrocardiogram: Left ventricular hypertrophy and left atrial enlargement may appear depending on the degree of regurgitation or outflow tract obstruction. In mild cases the ECG may be normal.

Chest X-ray: Cardiomegaly, left atrial enlargement and pulmonary venous congestion appear depending on severity.


8. Screening

Q23.8 malformations are mostly diagnosed following detection of a heart murmur, and systematic population-wide screening is not performed.

Auscultation of newborns and children: Detection of a systolic or diastolic murmur is the first clue. In children with a heart murmur, echocardiography confirms the underlying malformation.

Incidental detection in adults: Some malformations such as quadricuspid aortic valve are found incidentally in adulthood on echocardiography or cardiac CT. In such cases, the severity of regurgitation and the presence of associated malformations are evaluated.

Identification of high risk for infective endocarditis prevention: In patients with a confirmed dysplastic valve, endocarditis risk is assessed and prevention guidelines are provided.


9. Diagnosis

Echocardiography: The diagnostic standard. Quadricuspid aortic valve is diagnosed by the characteristic X- or Y-shaped valve appearance in the aortic short-axis view. Color Doppler is used to classify regurgitation and evaluate its severity, and in LVOTO, Doppler measures peak outflow tract velocity and pressure gradient.

Cardiac MRI: Useful for detailed anatomical evaluation of the valve, precise calculation of regurgitant fraction and three-dimensional understanding of LVOTO anatomy.

Cardiac CT: Used preoperatively to confirm valve anatomy and whether there are anomalous coronary artery origins.

Cardiac catheterization: Performed when noninvasive tests are insufficient or for preoperative coronary angiography.


10. Treatment

Treatment of Q23.8 malformations is individualized according to anatomical type and the severity of regurgitation or stenosis.

Mild, asymptomatic: Progression is monitored with regular follow-up echocardiography. Prophylactic antibiotic administration is advised for those at risk of infective endocarditis.

Quadricuspid aortic valve regurgitation: Surgical valve replacement or repair is performed for severe regurgitation or decreased left ventricular function. Valve repair is attempted depending on valve structure, but replacement is needed when dysplasia is severe.

LVOTO due to accessory mitral valve tissue: When symptomatic or with a large pressure gradient, surgical excision (excision of accessory tissue) or removal of the anomalous chord is needed. Symptom relief may be attempted with β-blockers, but the definitive treatment is surgery.

When complicated by infective endocarditis: Aggressive antibiotic treatment and emergency surgical correction if needed.


11. Prognosis

The prognosis of Q23.8 malformations differs greatly depending on anatomical type and the timing of diagnosis and treatment.

Quadricuspid aortic valve: When regurgitation is mild, it remains stable for decades with a good prognosis. When regurgitation progresses and surgery is needed, prognosis after valve replacement is good, similar to other valve replacement patients. Complication by infective endocarditis is the main risk.

LVOTO due to accessory mitral valve tissue: Prognosis after early surgical correction is relatively good, but follow-up is needed because of the possibility of residual or recurrent obstruction.

Overall, with regular follow-up and timely surgery, near-normal life expectancy is achievable in most patients with Q23.8 malformations. Prevention of infective endocarditis plays an important role in long-term prognosis.


12. Prevention

Primary prevention of Q23.8 malformations themselves is not possible.

Prevention of infective endocarditis: When a dysplastic valve is confirmed, prophylactic antibiotics before invasive procedures in high-risk groups (after valve replacement, history of endocarditis).

Regular follow-up: Regular echocardiography to track progression of the condition after a dysplastic valve is confirmed. Mild: every 3~5 years; moderate: every 1~2 years.

Exercise restriction: With severe regurgitation or LVOTO, restriction of high-intensity exercise and provision of activity guidelines after individual evaluation.

Pregnancy planning: With moderate or greater dysplasia, evaluation by a cardiologist is performed before pregnancy.


13. References

  1. Timperley J, Milner R, Marshall AJ, Gilbert TJ. Quadricuspid aortic valves. Clin Cardiol. 2002;25(12):548-552. DOI: 10.1002/clc.4960251203. PMID: 12489679.

  2. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39(12):1890-1900. PMID: 12084585.

  3. Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for adult congenital heart disease. Eur Heart J. 2021;42(6):563-645. DOI: 10.1093/eurheartj/ehaa554. PMID: 32860028.

  4. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for Valvular Heart Disease. J Am Coll Cardiol. 2021;77(4):e25-e197. DOI: 10.1016/j.jacc.2020.11.018. PMID: 33342586.

  5. Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for Adults with Congenital Heart Disease. J Am Coll Cardiol. 2008;52(23):e143-e263. PMID: 19038677.

  6. Garg V, Muth AN, Ransom JF, et al. Mutations in NOTCH1 cause aortic valve disease. Nature. 2005;437(7056):270-274. PMID: 16025100.

  7. Carpentier A, Branchini B, Cour JC, et al. Congenital malformations of the mitral valve in children. J Thorac Cardiovasc Surg. 1976;72(6):854-866. PMID: 993139.

  8. Lancellotti P, Tribouilloy C, Hagendorff A, et al. Recommendations for echocardiographic assessment of native valvular regurgitation. Eur J Echocardiogr. 2013;14(7):611-644. PMID: 23733442.

  9. Oppido G, Davies B, McMullan DM, et al. Surgical treatment of congenital mitral valve disease. Ann Thorac Surg. 2008;85(1):S800-S809. PMID: 18374004.

  10. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368(9540):1005-1011. DOI: 10.1016/S0140-6736(06)69208-8. PMID: 16980116.